Treatment of hemangioma by transfection of antisense VEGF gene

Abstract

The effect of transfection of antisense vascular endothelial growth factor (VEGF) gene on the growth of hemangioma was studied. A total of 49 cases of capillary hemangiomas of the skin were collected. Immunohistochemical method was used to detect the expression of PCNA in hemangioma tissues. According to the finding, 49 cases of hemangiomas fell into proliferating phase (27 cases) and involuting phase (22 cases) respectively. Another 5 cases of normal skin tissues adjacent to the tumor tissues served as control. Immunohistochemical staining was performed to detect the expression of VEGF in the tumor tissues and the normal tissues. The average absorbance (A) values and the average positive area rate of VEGF were measured by image analysis system (HPIAS-2000). Endothelial cells from the tumor tissues in proliferating phase were cultured. Eukaryotic expression vector was constructed by sub-cloning, and transfected into human hemangioma endothelial cells by using cation liposome as vector. The expression of VEGF mRNA and protein was detected by RT-PCR and indirect immunofluorescence assay (IFA), respectively, and the biological characteristics of the transfected endothelial cells were examined by MTT assay and flow cytometry (FCM) after transfection. Immunohistochemical results showed that the expression of VEGF in proliferating endothelial cells was remarkably higher than those in involuting endothelial cells and normal endothelial cells (P<0.01), but there was no significant difference in the expression of VEGF between involuting endothelial cells and normal ones (P>0.01). Electrophoresis and sequencing indicated that the eukaryotic expression vector containing antisense VEGF gene, i.e. pcDNA3.1-VEGF, was successfully constructed. After VEGF antisense RNA recombinant was transfected into hemangioma endothelial cells, RT-PCR revealed that the expression of VEGF mRNA in pcDNA-VEGF (V) group and blank group was obviously higher than that in pcDNA-VEGF (A) group, and that the expression of endogenous VEGF mRNA in pcDNA-VEGF (A) group was significantly inhibited. Immunohistochemical result demonstrated that, compared with blank group, there was statistically significant difference between pcDNA-VEGF (A) and pcDNA-VEGF (V) groups (P<0.01), but there was no significant difference between pcDNA-VEGF (V) group and blank group (P>0.05). The activity of endothelial cell proliferation was reduced significantly after transfection, and obvious apoptosis occurred in hemangioma endothelial cells after transfection of antisense VEGF. It was suggested that VEGF plays an important role in the pathological change of hemangiomas by promoting endothelial cell proliferation and angiogenesis. Antisense VEGF gene transfection could effectively inhibit the growth of hemanioma endothelial cells.

Keywords

VEGF / hemangioma endothelial cells / antisense, targeting vascular therapy

References

[1] GiatromanolakiA., ArvanitidouV., HatzimichaelA., et al. . The HIF-2alpha/VEGF pathway activation in cutaneous capillary haemangiomas. Pathology, 2005, 37(2): 149-151

[2] ZhangL., LinX., WangW., et al. . Circulating level of vascular endothelial growth factor in differentiating hemangioma from vascular malformation patients. Plast Reconstr Surg, 2005, 116(1): 200-204

[3] MarchukD.A.. Pathogenesis of hemangioma. J Clin Invest, 2001, 107(6): 665-666

[4] YuY., FlintA.F., MullikenJ.B., et al. . Endothelial progenitor cells in infantile hemangioma. Blood, 2004, 103(4): 1373-1375

[5] RiniB.I.. VEGF-targeted therapy in metastatic renal cell carcinoma. Oncologist, 2005, 10(3): 191-197

[6] MatsuiT., OnoT., KitoM., et al. . Extensive facial strawberry mark associated with cerebellar hypoplasia and vascular abnormalities. J dermatol, 1997, 24(2): 113-116

[7] YuY., FlintA.F., MullikenJ.B., et al. . Endothelial progenitor cells in infantile hemangioma. Blood, 2004, 103(4): 1373-1375

[8] PetrovaT.V., MakinenT., AlitaloK.. Signaling via vascular endothelial growth factor receptors. Exp Cell Res, 1999, 253(1): 117-130

[9] MatsunoA., NagashimaT.. Specific gene suppression using antisense strategy for growth suppression of glioma. Med Electron Microsc, 2004, 37(3): 158-161

[10] GuZ.P., WangY.J., WuY., et al. . Synthesis of ribozyme against vascular endothelial growth factor165 and its biological activity in vitro. World J Gastroenterol, 2004, 10(10): 1495-1498

[11] Glade-BenderJ., KandelJ.J., YamashiroD.J.. VEGF blocking therapy in the treatment of cancer. Expert Opin Biol Ther, 2003, 3(2): 263-276

[12] UnderinerT.L., RuggeriB., GingrichD.E.. Development of vascular endothelial growth factor receptor (VEGFR) kinase inhibitors as anti-angiogenic agents in cancer therapy. Curr Med Chem, 2004, 11(6): 731-745

[13] DvorakA.M., FengD.. The vesiculo-vacuolar organelle (VVO). A new endothelial cell permeability organelle. Histochem Cytochem, 2001, 49(4): 419-432

[14] Qu-Hong, NagyJ.A., SengerD.R.. Ultrastructural localization of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) to the abluminal plasma membrane and vesiculovacuolar organelles of tumor microvascular endothelium. Histochem Cytochem, 1995, 43(4): 381-389

[15] TrisciuoglioD., IervolinoA., ZupiG., et al. . Involvement of PI3K and MAPK signaling in bcl-2-induced vascular endothelial growth factor expression in melanoma cells. Mol Biol Cell, 2005, 6(9): 4153-4162

[16] KumarP., MillerA.I., PolveriniP.J.. MAPK mediates gamma-irradiation-induced endothelial cell apoptosis, and vascular endothelial growth factor protects endothelial cells through the phosphoinositide 3-kinase-Akt-Bcl-2 pathway. J Biol Chem, 2004, 279(41): 43352-43360

[17] NorJ.E., ChristensenJ., MooneyD.J., et al. . Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. Am J Pathol, 1999, 154(2): 375-384